Your session is about to expire
← Back to Search
PRN473 (SAR444727) for Atopic Dermatitis
Study Summary
This trial is studying the safety and effectiveness of an investigational drug called PRN473 in people with Alzheimer's disease.
- Atopic Dermatitis
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2022 Phase 2 trial • 39 Patients • NCT04992546Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
What criteria must be met in order to become a participant of this research experiment?
"This experimental therapy is recruiting 40 individuals between 18 and 70 years of age that are diagnosed with dermatitis. The proper selection criteria must be met, including: having two target lesions no further than 1 point apart on the trunk or upper extremities (excluding palms), being in generally good health as judged by a medical professional, an affected body surface area of at least 1% but not more than 14%, a validated Investigator Global Assessment-atopic dermatitis score of moderate or mild at screening, if female, proof of negative pregnancy test and agreement to practice abstinence/effective contraceptive use for 4 weeks prior to visit, and stable disease with no significant"
How many healthcare facilities are administering this research?
"24 medical centres are recruiting patients for this trial, including Investigational Site Number :8400013 in Tampa, California Allergy & Asthma Medical Group-Site Number:8400008 in Los Angeles, and Florida International Research Center-Site Number:8400017 in Miami. Moreover, many other locations have joined the study as well."
Is this investigation extending recruitment to those aged 80 or over?
"This clinical trial has set the lower and upper bounds of eligible participants at 18 years old and 70, respectively."
What risks and hazards are associated with the administration of PRN473 (SAR444727)?
"Due to the lack of existing clinical data validating PRN473 (SAR444727) efficacy, its safety was judged a 2 on the scale. However, there is evidence that it can be used without causing harm."
Are there still opportunities available for individuals to join this research program?
"Currently, this medical trial is recruiting participants. It was initially advertised on August 13th 2021 with the last update being made on October 26th 2022 according to clinicaltrials.gov information."
What is the enrollment capacity for this research project?
"To commence the trial, 40 eligible participants are necessary. Principia Biopharma, a Sanofi Company is responsible for coordinating and supervising the operation of this study from sites like 8400013 in Tampa, Florida and California Allergy & Asthma Medical Group-Site Number:8400008 in Los Angeles."
Share this study with friends
Copy Link
Messenger